Incidence of CXCR4 Tropism and CCR5-tropic Resistance in Treatment-Experienced Participants Receiving Maraviroc in the 48-Week MOTIVATE 1 and 2 Trials

Antiviral Chemistry and Chemotherapy - United Kingdom
doi 10.1177/2040206619895706